Dyne Therapeutics (DYN) Return on Capital Employed (2020 - 2026)
Dyne Therapeutics (DYN) recorded quarterly Return on Capital Employed of 43.53% in Q1 2026, up 9.22% quarter-over-quarter from 47.95% in Q4 2025, and up 1552.0% on a YoY basis from 2.64% in Q1 2025.
Dyne Therapeutics (DYN) Return on Capital Employed (2020 - 2026) Analysis & Trends
Dyne Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 43.53% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 1552.0% year-over-year to 43.53%; the TTM figure through Mar 2026 stood at 43.53% (up 1552.0% YoY), while the FY2025 annual figure was 52.7%, up 3642.0% from the prior year.
- Return on Capital Employed was 43.53% for Q1 2026 at Dyne Therapeutics, up from 47.95% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 41.69% in Q3 2024 to a low of 180.63% in Q4 2023.
- Historically, Return on Capital Employed has averaged 67.31% across 5 years, with a median of 60.85% in 2025.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 11844 bps in 2023, then soared 13064 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 62.19% in 2022, then sank by 190 bps to 180.63% in 2023, then surged by 72 bps to 49.99% in 2024, then climbed by 4 bps to 47.95% in 2025, then rose by 9 bps to 43.53% in 2026.
- The last three Return on Capital Employed figures came in at 43.53% (Q1 2026), 47.95% (Q4 2025), and 60.85% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Dyne Therapeutics | 3.00 Bn | 3.00 Bn | - | -43.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.53% |
| Dec 31, 2025 | -47.95% |
| Sep 30, 2025 | -60.85% |
| Jun 30, 2025 | -64.49% |
| Mar 31, 2025 | -59.06% |
| Dec 31, 2024 | -49.99% |
| Sep 30, 2024 | -41.69% |
| Jun 30, 2024 | -42.07% |
| Mar 31, 2024 | -82.74% |
| Dec 31, 2023 | -180.63% |
| Sep 30, 2023 | -108.04% |
| Jun 30, 2023 | -77.91% |
| Mar 31, 2023 | -65.47% |
| Dec 31, 2022 | -62.19% |
| Sep 30, 2022 | -61.64% |
| Jun 30, 2022 | -54.18% |
| Mar 31, 2022 | -41.90% |
| Dec 31, 2021 | -35.93% |
| Sep 30, 2021 | -28.55% |
| Dec 31, 2020 | -16.45% |